Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review.
Invega Trinza
antipsychotic
long-acting injectable
paliperidone
schizophrenia
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2021
2021
Historique:
received:
24
04
2021
accepted:
23
08
2021
entrez:
8
10
2021
pubmed:
9
10
2021
medline:
9
10
2021
Statut:
epublish
Résumé
Given the typical age onset of schizophrenia, there are tremendous economic and social impacts that extend beyond the person and their families. One critical determinant of the diseases' impact is the patient's adherence to antipsychotic drug treatment. Approved in 2015 for the treatment of schizophrenia, paliperidone palmitate (Invega Trinza, a 3-month injection, noted as PP3M) is a second-generation long-acting injectable antipsychotic medication. Among the different formulations offered for palmitate paliperidone, including the 1 and 3-month formulations, the longer duration 3-month formulation was better at preventing relapse in schizophrenic patients. To date, different formulations of palmitate paliperidone that have been studied on relapse episodes of schizophrenia include once-daily extended-release oral paliperidone (ORAL paliperidone), once-monthly paliperidone palmitate (PP1M), and once-every-3-months paliperidone palmitate (PP3M).
Identifiants
pubmed: 34621193
doi: 10.3389/fpsyt.2021.699748
pmc: PMC8490677
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
699748Informations de copyright
Copyright © 2021 Edinoff, Doppalapudi, Orellana, Ochoa, Patti, Ghaffar, Cornett, Kaye, Viswanath, Urits, Kaye and Kaye.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Curr Med Res Opin. 2017 Jun;33(6):1083-1090
pubmed: 28277864
Schizophr Res. 2013 Oct;150(1):3-10
pubmed: 23800613
Epidemiol Rev. 2008;30:67-76
pubmed: 18480098
J Clin Pharmacol. 2016 Mar;56(3):330-9
pubmed: 26189570
Int Clin Psychopharmacol. 2017 Nov;32(6):329-336
pubmed: 28806194
Early Interv Psychiatry. 2019 Jun;13(3):667-672
pubmed: 29968279
J Clin Psychiatry. 2017 Jul;78(7):e813-e820
pubmed: 28640988
Drug Dev Res. 2016 Nov;77(7):357-367
pubmed: 27633376
Clin Pharmacokinet. 2017 Apr;56(4):421-433
pubmed: 27743205
Int J Neuropsychopharmacol. 2016 Jul 05;19(7):
pubmed: 26902950
Braz J Psychiatry. 2019 Nov-Dec;41(6):499-510
pubmed: 30994855
J Clin Psychiatry. 2016 Jun;77(6):764-71
pubmed: 27135986
JAMA Psychiatry. 2017 Jul 1;74(7):686-693
pubmed: 28593216
Int J Mol Sci. 2017 Aug 03;18(8):
pubmed: 28771182
Psychiatr Clin North Am. 2007 Sep;30(3):323-38
pubmed: 17720026
J Clin Psychiatry. 2015 May;76(5):554-61
pubmed: 25938474
Drugs R D. 2015 Jun;15(2):163-74
pubmed: 25943458
Am J Manag Care. 2020 Mar;26(3 Suppl):S62-S68
pubmed: 32282176
J Clin Psychiatry. 2014;75 Suppl 2:30-3
pubmed: 24919169
Lancet. 2004 Jun 19;363(9426):2063-72
pubmed: 15207959
Schizophr Bull. 2016 Nov;42(6):1438-1445
pubmed: 27086079
Psychopharmacol Bull. 2017 May 15;47(2):42-52
pubmed: 28626271
Am Heart J. 2005 Dec;150(6):1115-21
pubmed: 16338246
Lancet. 2017 Sep 16;390(10100):1211-1259
pubmed: 28919117
Expert Opin Emerg Drugs. 2014 Dec;19(4):511-31
pubmed: 25234340
Perspect Psychiatr Care. 2018 Oct;54(4):530-538
pubmed: 29446084
CNS Neurol Disord Drug Targets. 2017;16(8):900-906
pubmed: 28758583
Clin Drug Investig. 2018 Aug;38(8):695-702
pubmed: 29882073
Molecules. 2018 Aug 20;23(8):
pubmed: 30127324
Schizophr Res. 2012 Sep;140(1-3):122-8
pubmed: 22809684
P T. 2016 Apr;41(4):222-7
pubmed: 27069340
Epidemiol Psychiatr Sci. 2017 Jun;26(3):231-233
pubmed: 28004623
Mol Psychiatry. 2013 Jan;18(1):53-66
pubmed: 22124274
J Psychiatr Res. 2019 Jul;114:105-112
pubmed: 31059990
JAMA Psychiatry. 2015 Aug;72(8):830-9
pubmed: 25820612
Int Clin Psychopharmacol. 2016 Jul;31(4):202-9
pubmed: 26974214
Int J Psychiatry Clin Pract. 2016;20(2):54-69
pubmed: 27052109
Curr Med Res Opin. 2016 Oct;32(10):1671-1679
pubmed: 27264496
J Psychiatry Neurosci. 2005 Nov;30(6):393-5
pubmed: 16327872
Seishin Shinkeigaku Zasshi. 2015;117(2):132-45
pubmed: 26514053
Psychiatry Clin Neurosci. 2015 Nov;69(11):661-73
pubmed: 26011091
Dialogues Clin Neurosci. 2010;12(3):271-87
pubmed: 20954425
Lancet. 1999 Apr 24;353(9162):1425-30
pubmed: 10227239
Am J Psychiatry. 2000 Apr;157(4):514-20
pubmed: 10739409
Brain. 2019 Dec 1;142(12):3669-3671
pubmed: 31789366
Schizophr Res. 2015 Oct;168(1-2):498-504
pubmed: 26232241
Curr Opin Psychiatry. 2016 May;29(3):224-9
pubmed: 26967313